MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Molecular testing for suspected hereditary transthyretin amyloidosis (hATTR) is covered when the patient has a clinical diagnosis of ATTR or presents with cardiac or progressive neuropathic features suggestive of hATTR combined with supporting factors (African American ancestry, first-degree relative with hATTR, or additional guideline-recognized features). Tests must be appropriate for clinical decision-making (include minimum guideline-based gene/variant content), be supported by documentation (counseling offered, results used for treatment, TA completion), and single-variant testing is allowed only for known familial variants.

"Patient has a clinical diagnosis of transthyretin amyloidosis (ATTR)."

Sign up to see full coverage criteria, indications, and limitations.